Asparia Glycomics S.L. is a spin-off company from CIC biomaGUNE, the Basque Center for Collaborative Biomaterials Research, founded in San Sebastian (Spain) in 2016 and set-up to produce and commercialize different lines of innovative solutions for glycan quantification and glycoproteomics.

Our mission is to bring glycan cancer biomarkers into the clinical mainstream by providing the cutting edge technology required for the absolute quantification of glycans by mass spectrometry.

The technology behind our products was invented in the Glycotechnology lab at CICbiomaGUNE and has been further developed into validated products now commercially available.